16.10.2020 • News

Barentz Buys US Maroon Group

Barentz, a Dutch distributor of life science ingredients, has agreed to acquire Maroon Group in the US for an undisclosed sum. The deal, which significantly extends Barentz’s footprint in North America, is expected to close by the end of this year.

Headquartered in Avon, Ohio, Maroon supplies specialty ingredients to the North American household, industrial & institutional (HI&I), personal care & pharmaceutical, food & nutrition, and coatings, adhesives, sealants and elastomers (CASE) markets. The company has an annual turnover of approximately $500 million and about 300 employees.

Maroon CEO Terry Hill said it was “a logical decision” to join with Barentz. He added: “The deciding factor was that Barentz is already a global business and this creates tremendous opportunities to strengthen our business in North America and internationally.” Hill and the Maroon management team will continue to manage operations.

The acquisition is expected to bring a series of synergies. “Our product portfolios are very complementary,” said Barentz CEO Hidde van der Wal, noting that there were no conflicts of interest between the two firms. “Maroon Group has significant scale in North America - the biggest economy of the world, where we were small, until today. The combination will immediately make Barentz a leading global distributor with an excellent opportunity to establish new business segments in North America.”

Maroon has been owned by US private equity firm CI Capital Partners, in partnership with the distributor’s management team, since 2014. Under CI’s ownership, Maroon has made 10 acquisitions.

Barentz also has private equity backing, from UK investment group Cinven, which took an undisclosed stake in November 2019.

 

Author: Elaine Burridge, Freelance Journalist

„Die von der EU-Kommission veröffentlichte Pharmastrategie muss die...
„Die von der EU-Kommission veröffentlichte Pharmastrategie muss die formulierten Ziele deshalb auch weiterhin mit Augenmaß und im Dialog mit den Stakeholdern umsetzen. Die Standortstärkung muss dabei Priorität haben“, sagt BPI-Hauptgeschäftsführer Kai Joachimsen. © REB Images/Getty Images 738779517

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read